Status:
UNKNOWN
Monitoring of COVID-19 Vaccine Response in Organ Transplant Patients
Lead Sponsor:
University Hospital, Strasbourg, France
Conditions:
Covid19
Kidney Transplantation
Eligibility:
All Genders
Brief Summary
Vaccination against SARS CoV-2 appears to be the best strategy today to control the COVID-19 pandemic. The first published studies with Pfizer, Moderna and Astra-Zeneca vaccines show very good vaccine...
Eligibility Criteria
Inclusion
- Patient, male or female, adult or child (15 years and older)
- Patient vaccinated against SARS-CoV-2 as part of routine care, and having received the 2 injections
- Solid organ transplant recipient
- Transplantation for more than 3 months
Exclusion
- History of anaphylactic shock or known allergy to PEG
- Known history of COVID or positive Covid serology in the 3 months preceding inclusion
- Formal contraindication to an intra-muscular injection
- Impossibility to give the subject informed information (subject in emergency situation, difficulties in understanding the subject, ...)
- Subject under legal protection
- Subject under guardianship or curatorship
- Patient having expressed his opposition to participate
Key Trial Info
Start Date :
February 9 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 1 2023
Estimated Enrollment :
3500 Patients enrolled
Trial Details
Trial ID
NCT04828460
Start Date
February 9 2021
End Date
February 1 2023
Last Update
November 9 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpitaux Universitaires de Strasbourg
Strasbourg, France, 67000